- Home
- / Amryt Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Amryt Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$222.5 M
FY, 2021
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
| Revenue | 14.5M | 58.1M | 182.6M | 222.5M |
| Cost of goods sold | 5.0M | 19.8M | 48.4M | 52.8M |
| Gross profit | 9.5M | 38.3M | 134.2M | 169.8M |
| Gross profit margin, % | 65.5% | 65.9% | 73.5% | 76.3% |
| Operating expense total | 33.3M | 65.2M | 110.0M | 155.0M |
| Depreciation and amortization | 310.0K | 23.6M | 70.6M | 53.4M |
| EBITDA | (23.9M) | (26.9M) | 24.1M | 14.8M |
| EBITDA margin, % | -165.2% | -46.3% | 13.2% | 6.6% |
| EBIT | (24.2M) | (58.7M) | (86.3M) | 21.3M |
| EBIT margin, % | -167.3% | -101.0% | -47.3% | 9.6% |
| Interest income | 5.0K | 92.0K | 87.0K | 5.0K |
| Interest expense | 1.4M | 8.6M | 22.4M | 23.8M |
| Pre tax profit | (25.7M) | (63.5M) | (105.9M) | (6.6M) |
| Income tax expense | 36.0K | (495.0K) | (1.3M) | (7.6M) |
| Net Income | (25.8M) | (63.0M) | (104.5M) | 1.0M |